TEVA
Teva Pharmaceutical-sp Adr
2 super-investors hold TEVA worth a combined $189M. The largest position: Harry Burn at 3.9% of their portfolio. This quarter the cohort logged 0 buys and 1 sell on the name. Cohort Conviction Score: 14 — ranked #708 of 724 scored stocks.
Why super-investors own TEVA
Interest in TEVA within this cohort is narrow and gradually cooling. Only two super-investors hold the stock — Harry Burn at 3.9% of his portfolio ($117M) and Stanley Druckenmiller at 2.4% ($72M) — for a combined $189M. Neither initiated nor added in 2026Q1; Druckenmiller trimmed his position, continuing a broader retreat that has seen cohort ownership fall from a peak of three holders to effectively a two-manager story with no new entrants in recent quarters. Burn remains the higher-conviction holder by concentration. The trend line — three owners two years ago, one for several consecutive quarters before Druckenmiller's re-entry, and now a trim — suggests fading rather than building enthusiasm across the group.
AI-synthesized from 13F filings. Not investment advice.
Cohort owners over time
2016Q4 → 2026Q1How many of the cohort members held this stock each quarter.
Owners (2) · click any column to sort
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Harry Burn | 3.9% | 11q | $117M | 3,885,683 |
| 2 | Stanley Druckenmiller | 2.4% | 7q | $72M | 2,377,285 |
Owners of TEVA also hold
Recent activity (1)
| Manager | Move | % Port. | Δ Shares | Value | Filed |
|---|---|---|---|---|---|
| Stanley Druckenmiller | TRIM | 2.4% | -60% | $72M | May 15, 2026 |
Long US equity 13F-HR filings only. CUSIP 881624209. Not investment advice.